SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453
http://www.w3.org/2000/01/rdf-schema#comment
"The new CRM1 inhibitors therefore hold strong potential and warrant further clinical investigations for PDAC."
xsd:string
http://purl.uniprot.org/uniprot/#_520A49E0C8C8046DF20DFC6F74C6F274EB728A8A491451306BC719E58B890EC1DA29030FEE6EBF58D2F6FA751597C074
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453
http://purl.uniprot.org/uniprot/A0A7I2V6B9
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453
http://purl.uniprot.org/uniprot/#_A0A7I2V6B9-mappedCitation-24899509
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/E7E00849133AD55456144FC26C30D8964FA451A6A567C25A0100F25C6F551FEB075BFBB5142FC0DC58CAFBE0B6809453